CJC-1295 + Ipamorelin (10 Mg)

CJC-1295 - GHRH Pathway Activator CJC-1295 is an analogue of Growth Hormone-Releasing Hormone (GHRH). It acts at the hypothalamic-pituitary interface, binding to GHRH receptors on pituitary somatotrophs. Its primary role:

• Increases GH pulse amplitude

• Extends the duration of GH release

• Enhances pituitary responsiveness to natural stimuli (sleep, exercise)

It represents the "permission signal" for GH secretion.

Ipamorelin - Ghrelin (GHS) Pathway Activator

Ipamorelin is a selective ghrelin receptor (GHS-R) agonist. Its defining features:

• Triggers GH release via a separate receptor system

• Extremely selective for GH (minimal cortisol or prolactin activity)

• Mimics the body's natural ghrelin-induced GH pulses

Ipamorelin provides the "trigger signal" that initiates each pulse.

Individually, each peptide stimulates GH. Together, they create physiological synergy. Dual-Pathway Activation

• CJC-1295 primes the pituitary and sustains signaling

• Ipamorelin initiates sharp, clean GH pulses

Because they act on different receptors, their effects are additive rather than redundant. This results in:

• Higher peak GH levels

• More frequent pulses

• Preservation of natural circadian rhythm

Importantly, GH release remains pulsatile, not continuous-critical for receptor sensitivity and long-term effectiveness

The enhanced GH pulses then:

• Act directly on fat metabolism (lipolysis, protein sparing)

• Stimulate hepatic production of IGF-1

• Support connective tissue, skin, and recovery processes

Because the signal originates endogenously:

• Feedback loops remain intact

• Somatostatin regulation is preserved

• Hormonal balance is maintained

This distinguishes the combination from exogenous GH, which bypasses pituitary intelligence entirely.